Teacher Retirement System of Texas increased its stake in shares of Exelixis Inc. (NASDAQ:EXEL) by 12.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,452 shares of the biotechnology company’s stock after buying an additional 3,448 shares during the period. Teacher Retirement System of Texas’ holdings in Exelixis were worth $246,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of EXEL. UBS Asset Management Americas Inc. increased its position in shares of Exelixis by 1,157.6% in the second quarter. UBS Asset Management Americas Inc. now owns 1,977,251 shares of the biotechnology company’s stock valued at $15,442,000 after buying an additional 1,820,029 shares during the last quarter. Oxford Asset Management increased its position in shares of Exelixis by 372.6% in the second quarter. Oxford Asset Management now owns 760,959 shares of the biotechnology company’s stock valued at $5,943,000 after buying an additional 599,945 shares during the last quarter. EAM Investors LLC increased its position in shares of Exelixis by 204.7% in the second quarter. EAM Investors LLC now owns 560,317 shares of the biotechnology company’s stock valued at $4,376,000 after buying an additional 376,427 shares during the last quarter. DIAM Co. Ltd. bought a new position in shares of Exelixis during the second quarter valued at $2,919,000. Finally, Alps Advisors Inc. bought a new position in shares of Exelixis during the second quarter valued at $2,510,000. Hedge funds and other institutional investors own 81.86% of the company’s stock.
Shares of Exelixis Inc. (NASDAQ:EXEL) opened at 11.67 on Wednesday. The company has a 50-day moving average price of $12.78 and a 200 day moving average price of $8.67. The company’s market capitalization is $2.69 billion. Exelixis Inc. has a 12-month low of $3.55 and a 12-month high of $15.58.
Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.11. The firm earned $36.25 million during the quarter, compared to analysts’ expectations of $16.76 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. Exelixis’s quarterly revenue was up 353.7% compared to the same quarter last year. On average, equities analysts anticipate that Exelixis Inc. will post ($0.61) earnings per share for the current fiscal year.
EXEL has been the subject of several analyst reports. S&P Equity Research raised their price target on Exelixis from $13.41 to $15.57 in a report on Wednesday, September 28th. Leerink Swann restated an “outperform” rating and set a $12.00 price target on shares of Exelixis in a report on Tuesday, September 20th. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, September 13th. Stifel Nicolaus lifted their price objective on Exelixis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Finally, Piper Jaffray Cos. reiterated a “neutral” rating and issued a $8.00 price objective (up from $5.00) on shares of Exelixis in a report on Thursday, August 4th. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $13.51.
In related news, insider Gisela Schwab sold 42,338 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $11.00, for a total transaction of $465,718.00. Following the completion of the sale, the insider now directly owns 174,354 shares in the company, valued at approximately $1,917,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by company insiders.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.